tesofensine and obesity treatment

In a study in the Lancet the value of the drug tesofensine which is an inhibitor of the presynaptic uptake of noradrenaline, dopamine and serotonin in weight reduction is reported. A dosage of 0.5 mg once daily along with an energy intake reduction could result in a weight loss over 24 weeks of 10%. The adverse effects were dry mouth, nausea, constipation hard stools diarrhoea and insomnia.. 21% withdrew from the trial.
The more unfortunate side effects of earlier drugs e.g agitation and anxiety were not seen.
An interesting study worth following and seeing the long term consequences, are these successes maintained?.
Astrup et al (2008) Effects of tesofensine on body weight loss, body composition and quality of life in obese patients: a randomised double blind , placebo controlled trial. Lancet. Vol 372 pp 1906-1913.
Bray 2008 Is new hope on the horizon for obesity? Lancet vol 372 1859-60.

Martin Eastwood
Back to top